Table 1.

Summary of the clinicopathologic feature of presenting patients with MMR deficient brain tumors.

#	Age	Sex	Diagnosis	Accompanying tumor	Site	Tumor size (cm)	MRI finding	Op	Postoperative treatment	Follow up	Presence of giant cells	MVP/necrosis	Ki67 index
1	47	F	GBM IDH-wt, rec	–	Lt. temporal	5	Rim enhancing mass and hemorrhage	GTR	CCRT/TMZ	Recur and died in 57 months after GTR	No (lipidized cells)	+/−	15.7%
2	41	F	GBM IDH-wt, rec	–	Rt. parietal	5.7	Heterogeneously enhancing mass	GTR	No adjuvant therapy	Died in 12 months after GTR	Yes	+/+	79.6%
3	75	F	GBM IDH-wt, rec, Lynch syndrome	Colon adenocarcinoma	Rt. temporal	5	Multifocal enhancing mass	GTR	CCRT/TMZ	Recur	Yes	+/+	24.1%
4	69	M	GBM IDH-wt, rec, Lynch syndrome	Multiple GI adenocarcinomas, prostatic carcinoma	Rt. occipital	6	Heterogeneous enhancing mass with perilesional edema	GTR	Hypo-CCRT/TMZ	Recur	Yes	+/+	88.8%
5	66	M	GBM IDH-wt, rec	–	Rt. frontal	5.3	Irregular enhancing mass	GTR	Hypo-CCRT/TMZ (Incomplete)	Recur	Yes	+/+	37.6%
6	73	F	GBM IDH-wt, rec	–	Rt. temporal	1.9	Rim enhancing irregular mass	GTR	PO-RT only	Recur	Yes	+/+	85.2%
7	58	M	GBM IDH-wt	–	Posterior fossaa	2.2	Enhancing mass	biopsy	CCRT/TMZ	Stationary in 4 months after biopsy	Yes	+/−	83.6%
8	50	F	GBM IDH-wt, Lynch syndrome	–	Lt. thalamus, basal ganglia, mid-brain	4.6	Enhancing mass lesion	GTR	CCRT/TMZ	Stationary in 3 months after GTR	Yes	+/+	63.8%
9	78	M	Gliosarcoma, IDH-wt, rec	MMRD after CCRT	Lt. cerebellum	4	Heterogeneous enhancing mass	GTR	CCRT/TMZ	Recur	Yes	+/+	18.2%
10	11	M	DMG H3 K27M-m, rec	–	Rt. thalamus	3.6	Multiple enhancing solid and cystic mass	GTR	CCRT/TMZ	Recur (×4) and died in 22 months after GTR	No	+/+	41.8%
11	33	M	Astrocytoma, IDH-m, WHO grade 4, rec	MMRD after CCRT	Rt. frontotemporal	8.5	Enhancing tumor	GTR	No adjuvant therapy	Recur and died in 59 months after GTR	No	+/+	43.1%
12	15	M	Astrocytoma, IDH-m, WHO grade 4, rec	–	Rt. frontal	3.4	Enhancing solid and cystic lesion	GTR	CCRT/TMZ	Recur	Yes	+/+	18.8%
13	35	F	Pleomorphic xanthoastrocytoma, Lynch syndrome	–	Rt. frontal, corpus callosum and cingulate gyrus	3.8	Subtle enhancing and cystic change	GTR	No adjuvant therapy	Stationary	Yes	−/−	2.2%

rec recurrent, GBM IDH-wt glioblastoma IDH-wildtype, DMG H3 K27M-m diffuse midline glioma H3 K27M-mutant, Posterior fossa^a 4th ventricle and right cerebellum and left vermis, GTR gross total resection, PO-RT postoperative radiotherapy, MVP microvascular proliferation, Op operation, + present, absent.